OSR (NASDAQ:OSRH) Issues Quarterly Earnings Results

OSR (NASDAQ:OSRH) announced its quarterly earnings data on Friday. The company reported ($0.02) earnings per share (EPS) for the quarter, FiscalAI reports. OSR had a negative net margin of 363.26% and a negative return on equity of 7.24%. The company had revenue of $0.32 million for the quarter.

OSR Price Performance

Shares of OSR stock traded up $0.03 during trading hours on Friday, reaching $0.31. The company’s stock had a trading volume of 2,565,207 shares, compared to its average volume of 3,339,401. The firm has a 50 day moving average price of $0.39 and a 200-day moving average price of $0.47. The stock has a market cap of $10.99 million, a P/E ratio of -0.95 and a beta of 0.56. OSR has a one year low of $0.25 and a one year high of $1.24.

Analysts Set New Price Targets

OSRH has been the topic of a number of research reports. Wall Street Zen upgraded shares of OSR from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of OSR in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP bought a new position in OSR Holdings, Inc. (NASDAQ:OSRH) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR as of its most recent filing with the SEC. 55.30% of the stock is owned by hedge funds and other institutional investors.

OSR Company Profile

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.